Napa, Calif. — At the fall Cosmetic Bootcamp (CBC), an expert explained how recent compounding regulations can help core aesthetic practices.
A relatively new section of the Federal Food, Drug and Cosmetic Act Section 503B allows physicians to order from FDA-registered 503B outsourcing facilities. Wm. Philip Werschler, M.D., said, “Congress and the FDA recognized the need for compounded medications but insisted that they be made in a quality environment.” He is a Spokane, Washington-based dermatologist in private practice and a clinical teaching professor at the University of Washington.
Rather than having to write individualized prescriptions that each patient would take to a compounding pharmacy, physicians now may keep approximately a 3-month supply of compounded inventory on hand. “That was a significant fundamental change in how a dermatology office operates.”
For additional details or to register for future CBC events, please contact:
CBC/Meeting Designs, LLC